Autor según el artículo: Rojas, ZH; Llorca, MRD; Martín, CA; Gonçalves, AQ; Casajuana, M; Fernández-Sáez, J; Cumplido, DR; Drago, EF; Carrasco-Querol, N; Vilaubí, JMP; Alegret, JM
Departamento: Medicina i Cirurgia
Autor/es de la URV: Alegret Colomé, Josep Maria
Palabras clave: Stroke prevention Primary health care Oral drug administration Management Guidelines Dabigatran Cost effectiveness Care Atrial fibrillation Anticoagulants
Resumen: BACKGROUND: Anticoagulant therapy is used for stroke prevention and proved to be effective and safe in the long term. The study aims to analyse the cost-effectiveness relationship of using of direct-acting oral anticoagulants vs vitamin K antagonists to prevent ischaemic stroke in patients with nonvalvular atrial fibrillation, including all the active ingredients marketed in Spain, prescribed for 2 years in the Primary Care service of the Institut Català de la Salut. METHODS: Population-based cohort study, in which the cost of the 2 treatment groups will be evaluated. Direct costs (pharmacy, primary care, emergency and hospitalization) and indirect costs (lost productivity) will be included from a social perspective. Effectiveness (assessed as the occurrence of a health event, the 1 of primary interest being stroke) will be determined, with a 2-year time horizon and a 3% discount rate. The average cost of the 2 groups of drugs will be compared using a regression model to determine the factors with the greatest influence on determining costs. We will carry out a univariate ('one-way') deterministic sensitivity analysis. DISCUSSION: We hope to provide relevant information about direct and indirect costs of oral anticoagulants, which, together with aspects of effectiveness and safety, could help shape the consensual decision-making of evaluating bodies.
Áreas temáticas: Saúde coletiva Odontología Nutrição Medicine, general & internal Medicine (miscellaneous) Medicine (all) Medicina iii Medicina ii Medicina i Matemática / probabilidade e estatística Interdisciplinar Geografía General medicine Farmacia Ensino Engenharias iv Enfermagem Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Astronomia / física Antropologia / arqueologia
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
Direcció de correo del autor: josepmaria.alegret@urv.cat
Identificador del autor: 0000-0002-6117-5512
Fecha de alta del registro: 2024-02-11
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://journals.lww.com/md-journal/Fulltext/2020/09040/Cost_effectiveness_of_direct_oral_anticoagulants.79.aspx
URL Documento de licencia: http://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Medicine. 99 (36): e22054-
Referencia de l'ítem segons les normes APA: Rojas, ZH; Llorca, MRD; Martín, CA; Gonçalves, AQ; Casajuana, M; Fernández-Sáez, J; Cumplido, DR; Drago, EF; Carrasco-Querol, N; Vilaubí, JMP; Alegret (2020). Cost-effectiveness of direct oral anticoagulants versus vitamin K antagonist in atrial fibrillation: A study protocol using Real-World Data from Catalonia (FantasTIC Study). Medicine, 99(36), e22054-. DOI: 10.1097/MD.0000000000022054
DOI del artículo: 10.1097/MD.0000000000022054
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2020
Tipo de publicación: Journal Publications
Repositori URV